Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Registry for Cirrhotic Subjects with Sustained Virologic Response After Sofosbuvir-Based Interferon-Free HCV Therapy
2014-001249-26Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sofosbuvir in chronic hepatitis C (CHC) and Hepatitis C-related cirrhosis, sponsored by Gilead Sciences. Primary endpoint: Durability of Sustained Virologic Response. Started Apr 2015; status: completed.
02
Drugs
sofosbuvir
03
Conditions
chronic hepatitis C (CHC)Hepatitis C-related cirrhosis
Beyond the preview
Go deeper on 2014-001249-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001249-26.